Detail akcie Minerva Neurosci Rg online

Business Summary: Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and ?-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Minerva Neurosciences Inc revenues was not reported. Net loss totaled $9.8M vs. income of $5.7M. Net loss reflects Investment income decrease of 61% to $402K (income), Foreign exchange losses increase from $12K to $36K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.75 to -$1.29.